DSF/Cu can inhibit ALDH‐positive NSCLC tumors. The combination of DSF and gemcitabine efficiently inhibits breast tumors; the combination of TMZ and DSF/Cu in a Phase II clinical trial (NCT03034135) rescue ALDH1A3‐mediated TMZ resistance in GBM patients. Here, LDHA is linked to non-small cell lung carcinoma.